Liraglutide is the drug that came before the current generation, and it is easy to overlook now that weekly injections dominate the conversation. For the alcohol question it deserves better, because some of the most relevant brain research in this whole class was done with it. This article is part of our GLP-1 and Alcohol hub.
Victoza is liraglutide for type 2 diabetes. Saxenda is the same molecule at a higher dose for weight management. Both are daily injections rather than weekly.
# Why liraglutide matters to this question
The mechanism argument for GLP-1 drugs affecting alcohol rests on these drugs acting in the brain’s reward circuitry, not just in the gut. Liraglutide is one of the molecules where that has been examined most directly in humans.
Brain-imaging studies in people have shown liraglutide altering responses to food cues in reward-related regions. That work was about eating rather than drinking, but it addresses the step in the argument that is hardest to demonstrate: that these drugs reach and influence the relevant circuitry in an actual human brain rather than only in a rodent one.
For the alcohol question specifically, that makes liraglutide useful supporting evidence for the mechanism described in the hub overview, even though it is not itself evidence about drinking.
# What exists on liraglutide and alcohol
Being straightforward about it: less than you would hope, and less than for semaglutide.
Animal studies exist and point the same way as the rest of the class. Liraglutide appears in rodent work on alcohol intake with results broadly consistent with the GLP-1 literature generally.
Human alcohol trials are essentially absent. There is no randomized trial of liraglutide for alcohol use disorder comparable to the semaglutide trial published in JAMA Psychiatry in 2025.
Patient reports are thinner than for the newer drugs, largely because far fewer people take liraglutide now. Prescribing has shifted toward weekly semaglutide and tirzepatide, so the pool of people who might notice and report an alcohol effect is much smaller.
That last point is worth pausing on. The volume of patient reports about a drug reflects how many people take it at least as much as how strong its effect is. Semaglutide dominates the anecdotal evidence partly because semaglutide dominates prescriptions. Absence of chatter about liraglutide is weak evidence of absence of effect.
# The daily dosing difference
Liraglutide is injected daily, which sets it apart from everything else in current use for this purpose.
That produces a steadier concentration than the weekly drugs, which peak in the days after each injection and drift down before the next. If the alcohol effect depends on sustained receptor activation, a steady daily level is at least a different exposure pattern, and possibly a more consistent one. Whether that translates into anything for drinking has not been studied.
The practical trade is the obvious one: a daily injection is a bigger commitment than a weekly one, and adherence tends to be worse. It is one reason prescribing has moved on.
# Saxenda and Victoza are the same drug
The pattern is identical to Ozempic and Wegovy. Victoza is liraglutide licensed for type 2 diabetes; Saxenda is liraglutide licensed for weight management and titrated to a higher daily dose.
That distinction carries the same implication it does for semaglutide. If the alcohol effect strengthens with dose, as the broader pattern in this class suggests, then someone on Saxenda maintenance is further along that curve than someone on a diabetes dose of Victoza. Two people can both say they take liraglutide and be having quite different pharmacological experiences.
It also means that if you are comparing your experience with someone else’s, the brand name tells you more about their indication than about their dose, and neither tells you where they are in titration.
# Where liraglutide sits in the class
Placed against the others, liraglutide occupies an unusual position: relatively strong mechanistic support, relatively weak alcohol-specific evidence.
The brain-imaging work gives it better human evidence than most of the class for the step the whole hypothesis depends on, which is that these drugs influence reward processing in people rather than only in rodents. Semaglutide has more evidence that drinking actually changes. Those are different claims, and liraglutide is stronger on the first and weaker on the second.
For a reader, the useful takeaway is that the argument for expecting something from liraglutide is a mechanistic argument rather than an empirical one. That is a weaker basis than a trial, and a stronger basis than nothing.
# Side effects and drinking
Liraglutide carries the same gastrointestinal profile as the rest of the class: nausea most commonly, particularly during the dose-escalation period, along with vomiting, diarrhea and constipation for some.
The interaction with alcohol is the same as for the newer drugs, and is covered in can you drink alcohol on a GLP-1. The point that matters most applies here too: if you take insulin or a sulfonylurea alongside it, alcohol raises the risk of hypoglycaemia, and that combination needs your own doctor’s advice rather than an article.
One difference worth knowing is that a daily injection means daily titration decisions rather than weekly ones, so the escalation period can feel more relentless even though the endpoint is similar.
# Should anyone choose it for the alcohol effect?
No, and the reasoning is the same as for every drug in this hub.
Nothing in this class is licensed for alcohol use disorder, and liraglutide has less alcohol-specific evidence than semaglutide rather than more. If you are on it for diabetes or weight and you notice your drinking change, that is an observation to record and report. If you want a medication aimed at drinking, the licensed options are set out in GLP-1 vs naltrexone for alcohol cravings.
There is one situation where liraglutide comes up legitimately: people who cannot tolerate or cannot access the newer drugs. Supply problems and cost have pushed some patients back toward liraglutide, and if that is you, the mechanism argument applies to your drug as much as to anyone else’s. What you do not have is trial evidence specific to it.
# If you are taking it and drinking less
Record it, note your dose changes, and raise it at your next appointment. The reasoning is in which GLP-1 medications have evidence for alcohol cravings, but it is worth saying that this is more valuable for liraglutide than for semaglutide, precisely because so few people are reporting it.
A single person’s log is not research. But the reason liraglutide’s alcohol evidence is thin is partly that hardly anyone is looking, and a documented pattern you can show a clinician is a more useful contribution than a vague impression.
# How AlcoLog helps
Daily dosing makes a log more useful, not less, because there is no weekly rhythm to anchor your memory to.
AlcoLog tracks medication doses, including GLP-1 agonists, alongside every logged drink. One tap logs a drink. The dose timeline and the drinking timeline sit together, so an escalation step and the weeks after it can be compared directly rather than recalled.
Weekly and monthly views make a gradual change visible. If your drinking has moved, it shows as a trend rather than a feeling, and that is what makes it worth showing to a prescriber.
The AlcoScore deliberately excludes medication. Your dose log is there to inform you, not to be graded. Everything stays on your device with no account or email, and export is available when you want to share something concrete.
